771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors

• Evan Hall,
• Adi Diab,
• Sajeve Thomas,
• Randy Sweis,
• Anthony El-Khoueiry,
• Naveen K Mehta,
• Jennifer S Michaelson,
• Laura Liu,
• Reham Abdel-Wahab,
• Jeffrey A Jones,
• Kaida Wu,
• Benjamin S Maciejewski

Affiliations

Evan Hall

5Seattle Cancer Care Alliance, Seattle, WA, USA

Adi Diab

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Sajeve Thomas

5Orlando Health Cancer Institute, Orlando, FL, USA

Randy Sweis

6The University of Chicago, Chicago, IL, USA

Anthony El-Khoueiry

4USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Naveen K Mehta

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Jennifer S Michaelson

5Cullinan Oncology, Inc., Cambridge, MA, USA

Laura Liu

Bristol Myers Squibb Co, Princeton, New Jersey, USA

Reham Abdel-Wahab

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jeffrey A Jones

1Cullinan Oncology, Inc., Cambridge, MA, USA

Kaida Wu

5Cullinan Oncology, Inc., Cambridge, MA, USA

Benjamin S Maciejewski

6The University of Chicago, Chicago, IL, USA